GBG HOME

May 2022: Effect of denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy for primary breast cancer – results from GeparX trial

31.05.2022

We are pleased to inform you that primary results from GeparX trial have been published in JAMA Oncology.

The GeparX (NCT02682693) was a multicenter, prospective, open-label, phase 2b, 2 × 2 randomized clinical trial conducted by GBG and AGO-B at 38 German sites between February 2017 and March 2019. Eligible patients had unilateral or bilateral primary breast cancer, stage cT2-cT4a-d or cT1c, with either clinically node-positive or pathologically node-positive or HR-negative disease, or Ki-67 proliferation index greater than 20%, or HER2-positive breast cancer. Primary objective was to determine whether adding denosumab to anthracycline/taxane-containing neoadjuvant chemotherapy increases the pathological complete response (pCR) rate and which nab-paclitaxel schedule is more effective in this neoadjuvant setting.

Highlights:

  • Denosumab added to anthracycline/taxane-based neoadjuvant chemotherapy does not improve pCR rates.
  • Nab-paclitaxel weekly significantly (α=0.10) increases pCR rates compared to d1,8 q3w, especially in TNBC.
  • High-grade toxicity did not differ with or without denosumab.
  • The rate of high-grade nonhematologic adverse events was significantly higher with nab-paclitaxel weekly compared to d1,8 q3w (33.7% vs 24.1%; p=0.004).


Conclusion: In the GeparX trial, denosumab added to anthracycline/taxane-based neoadjuvant chemotherapy did not improve pCR rates. Nab-paclitaxel at a dosage of 125 mg/m2 weekly significantly increased the pCR rate compared with the days 1 and 8, every-3-weeks schedule overall and in TNBC, but generated higher toxicity.

Blohmer JU, Link T, Reinisch M, et al. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1010-1018. doi: 10.1001/jamaoncol.2022.1059.


News

  • 18.11.2022 Desiree: dose escalation of everolimus published

    Desiree: dose escalation of everolimus published

    We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.

    Mehr ...
  • 10.11.2022 Deutscher Krebskongress

    Deutscher Krebskongress

    Die GBG ist mit mehreren Postern auf dem 35. Deutschen Krebskongress vom 13. – 16. November 2022 in Berlin vertreten.

    Mehr ...
  • 08.11.2022 GBG research at SABCS 2022

    GBG research at SABCS 2022

    We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10

    Mehr ...
  • 14.10.2022 Location of Subcutaneous Trastuzumab Injection

    Location of Subcutaneous Trastuzumab Injection

    Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study

    Mehr ...

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd